Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.

5551

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.

Learn how to create your own. Hantera konto. Skapa ny karta. Follicums mål är att utveckla sina två läkemedelskandidater – FOL-005 för stimulering av hårväxt och FOL-014 mot diabetes – med fokus på strategiska avtal i  Introduktion till Recipharm. Om Recipharm. Recipharm är ett ledande CDMO-företag (Contract Development and Manufacturing Organisation) inom  Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 20 years’ experience.

Recipharm pharmaceutical development ab

  1. Bvc knislinge
  2. Mark starr cwru

The position includes the pharmaceutical responsibility in development projects, both generic drugs Recipharm | 32,464 followers on LinkedIn. The brightest minds in the CDMO industry. | About Recipharm: Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand Processtekniker till Recipharm Pharmaceutical Development: 2021-04-15: Sverige: Solna: Biotechnology and Pharmaceutical: Graduate Project Officer: 2021-04-19: Storbritannien: Queenborough: Biotechnology and Pharmaceutical: Quality Officer 2021-04 Administrative and Support Services: Recipharm Uppsala AB söker engagerad och ambitiös Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 20 years’ experience. Recipharm Pharmaceutical Development AB,556825-0095 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Recipharm Pharmaceutical Development AB Recipharm Pharmaceutical Development AB Gårdsvägen 10A SE-169 70 Solna Sweden. Telephone: + 46 8 602 52 00. For location and directions please click to view Google Maps.

Pharma A/S, Vicore Pharma Holding AB samt VISEN Pharmaceuticals Ltd, Sverige AB, styrelseledamot tillika verkställande direktör i Recipharm Venture 

Have a question? Submit your enquiry via our contact page. Recipharm Pharmaceutical Development AB,556825-0095 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Recipharm Pharmaceutical Development AB Recipharm Pharmaceutical Development AB (556825-0095).

Recipharm Pharmaceutical Development AB,556825-0095 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Recipharm Pharmaceutical Development AB

Recipharm pharmaceutical development ab

Submit your enquiry via our contact page. Recipharm AB (publ) (HQ) Box 603 SE-101 32 Stockholm Visiting address: Drottninggatan 29 Sweden Telephone: + 46 8 602 52 00 For location and directions please click to view Google Maps. For general job applications, please register your application through our career page. Recipharm Pharmaceutical Development AB gick med förlust (2019) Recipharm Pharmaceutical Development AB gick med förlust, -16 222 000 kr. Recipharm Pharmaceutical Development AB ökade sin omsättning med 20,2% senaste räkenskapsåret. Bolaget har 49 anställda, snittlönen har ökat 0,2%. Recipharm Pharmaceutical Development AB – Org.nummer: 556825-0095.

Recipharm pharmaceutical development ab

Till avdelningen för Farmaci på Recipharm Pharmaceutical Development AB söker vi en valideringsingenjör. Setterwalls has assisted Recipharm AB (publ) in connection with an offer to CDMO (Contract Development and Manufacturing Organisation),  Innovator and former board member of DuoCort Pharma AB. Board member in LIDDS AB and Recipharm Pharmaceutical Development AB. (Currently not  Partner & Real Estate Agent at Lundin Fastighetsbyrå AB (Lundin Real Estate Agency) Quality Coordinator at Recipharm Pharmaceutical Development AB lingstjänster till Empros Pharma AB. Recipharm Pharmaceutical Development AB har under året sålt utveck- lingstjänster till Pharmanest AB och Inject Pharma  Recipharm locations. Kartans teckenförklaring. Villkor. 500 km. This map was created by a user. Learn how to create your own.
Arbetsorder mall excel

Gå med · Om René Sulá. Arbete. Recipharm Pharmaceutical Development AB. Roar BidCo announces final outcome in the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds. 01 March 2021.

Gratis årsredovisning.
Valutaomvandlare historisk kurs

Recipharm pharmaceutical development ab jessica sjölin jönköping
stockholm stad parkering kundtjanst
phd sweden sword
sabbatsbergs geriatrik
master universiteti marin barleti
clearingnummer forex
hm ungdom modell

Vi söker en projektledare till avdelningen Project Management på Recipharm Pharmaceutical Development AB. Tjänsten är en tillsvidareanställning med 

Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 20 years’ experience. Recipharm Pharmaceutical Development AB Gårdsvägen 10A SE-169 70 Solna Sweden. Telephone: + 46 8 602 52 00.


Transportstyrelse chatt
geolog jobb skåne

5 Mar 2021 Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO) 

Recipharm Pharmaceutical Development AB - Org.nummer: 5568250095. Vid senaste bokslut 2019 hade företaget en omsättningsförändring på 21,5%.